☆ 4.8 Review

Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.
Review Biochemistry & Molecular Biology

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Karama Makni Maalej et al.

Summary: In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has shown efficacy in treating hematological malignancies, but its value in solid tumors remains inconclusive. The limitations of CAR-T cell therapy in solid tumors include limited tumor trafficking and infiltration, an immunosuppressive tumor microenvironment, and adverse events. CAR-NK and CAR-M cells have been introduced as alternative immunotherapies for solid tumors, with potential advantages such as no HLA compatibility requirement and limited toxicity for CAR-NK cells, and capabilities of phagocytosis, tumor-antigen presentation, and broad tumor infiltration for CAR-M cells. Prospective solutions, such as combination therapies, could enhance the efficacy of CAR-cell immunotherapy.

MOLECULAR CANCER (2023)

Add to Collection
Article Cell & Tissue Engineering

Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies

Jue Zhang et al.

Summary: In this study, anti-GD2 CAR was integrated into the AAVS1 locus of human pluripotent stem cells using CRISPR-Cas9 gene editing. A serum- and feeder-free differentiation protocol was established to generate CAR macrophages (CAR-Ms) through arterial endothelial-to-hematopoietic transition (EHT). The CAR-Ms produced using this method showed potent cytotoxic activity against GD2-expressing neuroblastoma and melanoma in vitro and neuroblastoma in vivo. This study provides a new platform for efficient generation of off-the-shelf CAR-Ms for antitumor immunotherapy.

STEM CELL REPORTS (2023)

Add to Collection
Review Immunology

Macrophages as a Potential Immunotherapeutic Target in Solid Cancers

Alok K. Mishra et al.

Summary: The revolution in cancer immunotherapy has resulted in a paradigm shift in cancer care, with a focus on targeting the components of the adaptive immune system. However, recent developments have recognized the efficacy of targeting the innate immune system, including macrophages, in solid cancer treatment. This review provides an overview of the role of tumor-associated macrophages (TAMs) in solid malignancies and discusses potential therapeutic strategies for targeting TAMs in next-generation immunotherapy.

VACCINES (2023)

Add to Collection
News Item Dermatology

CD19 CAR T cell therapy effective for systemic lupus erythematosus

J. Gelfand

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

Add to Collection
Article Medicine, Research & Experimental

M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors

Yi Huo et al.

Summary: This study developed a novel HER2-targeting CAR-M and demonstrated that M1 polarization enhanced the immune activity of CAR-M, resulting in effective elimination of HER2-positive tumor cells both in vitro and in vivo. This finding suggests that M1-polarized CAR-M has the potential to become a stronger therapeutic approach in solid cancer immunotherapy.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Add to Collection
Article Multidisciplinary Sciences

CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours

Bastian Kruse et al.

Summary: Most clinically applied cancer immunotherapies rely on direct recognition and killing of tumor cells by CD8(+) cytolytic T cells. However, the effectiveness of these strategies is limited by the emergence of MHC-deficient tumor cells and immunosuppressive tumor microenvironment. In this study, researchers have discovered that a small number of CD4(+) T cells can eliminate MHC-deficient tumors that escape CD8(+) T cell targeting. CD4(+) effector T cells cluster at tumor invasive margins and interact with MHC-II(+)CD11c(+) antigen-presenting cells, leading to the activation of tumoricidal myeloid cells. Together, CD4(+) T cells and tumoricidal myeloid cells induce inflammatory cell death and eradicate interferon-unresponsive and MHC-deficient tumors, suggesting a potential strategy to complement current cancer immunotherapies.

NATURE (2023)

Add to Collection
Article Multidisciplinary Sciences

CAR immune cells: design principles, resistance and the next generation

Louai Labanieh et al.

Summary: The development of next-generation CAR immune cell technologies has greatly improved the efficacy, safety, and accessibility of CAR therapies. Multispecific, logic-gated, and regulatable CARs show promise in overcoming resistance and increasing safety. Stealth, virus-free, and in vivo gene delivery platforms may reduce costs and improve access to cell therapies. The success of CAR T cells in liquid cancers is driving the development of more sophisticated immune cell therapies for solid cancers and non-malignant diseases in the future.

NATURE (2023)

Add to Collection
Article Cell Biology

Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia

Mayumi Sugita et al.

Summary: Autologous T cells engineered with CAR specific for CD19 have been approved for treating CD19(+) hematological malignancies. However, relapse often occurs when neoplastic cells lose CD19 expression. Preclinical models have shown that radiation therapy (RT) can overcome CD19 loss by inducing death receptor expression in cancer cells. Using a human model of CD19(+) acute lymphoblastic leukemia (ALL), it was found that low-dose total body irradiation (LD-TBI) administered before CAR T cell infusion significantly improved overall survival and CAR T cell expansion. These findings support the initiation of clinical trials combining LD-TBI with CAR T cells.

CELL DEATH & DISEASE (2023)

Add to Collection
Article Multidisciplinary Sciences

CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy

Yun Chang et al.

Summary: This study demonstrates the efficacy of neutrophil-mediated drug delivery for brain tumor treatment using CAR-modified neutrophils and chemodrug-loaded nanoparticles. The approach shows promising results in preclinical glioblastoma models and addresses the issue of blood-brain barrier restrictions.

NATURE COMMUNICATIONS (2023)

Add to Collection
Article Biotechnology & Applied Microbiology

Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2/Her2-specific CAR-macrophages for brainstem glioma immunotherapy

Lin Gao et al.

Summary: A synthetic universal DNA nanocarrier was developed for in situ genetic editing of macrophages (M phi s) within brain tumors, which directed their phagocytic activity towards tumors and initiated an antitumor immune response. This approach could potentially be applied to patients suffering from other ErbB2-positive solid malignancies, providing a practical antitumor immunotherapy for brainstem gliomas (BSGs).

JOURNAL OF NANOBIOTECHNOLOGY (2023)

Add to Collection
Article Multidisciplinary Sciences

Surficial nano-deposition locoregionally yielding bactericidal super CAR-macrophages expedites periprosthetic osseointegration

Ziyang Li et al.

Summary: Tracking and eradicating Staphylococcus aureus in the periprosthetic microenvironment is crucial for preventing periprosthetic joint infection (PJI), but effective strategies are still lacking. In this study, we present an implant nanoparticle coating that generates bactericidal super chimeric antigen receptor macrophages (CAR-M phi s) to prevent PJI. By introducing S. aureus-targeted CAR genes and CASP11 shRNA into macrophage nuclei, the coating allows the generation of super CAR-M phi s that efficiently target and eliminate S. aureus, providing robust bactericidal immune activity at the bone-implant interface. The coating also exhibits biodegradability that matches the bone regeneration process, facilitating satisfactory osteogenesis.

SCIENCE ADVANCES (2023)

Add to Collection
Review Immunology

Metabolic challenges and interventions in CAR T cell therapy

Jhan-Jie Peng et al.

Summary: Chimeric antigen receptor (CAR) T cells have achieved clinical success in treating hematological malignancy, but their efficacy in solid tumors remains challenging. This article reviews the metabolic stress and signaling in the tumor microenvironment that restrict the efficacy of CAR T cell therapy, and discusses novel approaches to target and rewire metabolic programming for CAR T cells. Strategies to improve the metabolic adaptability of CAR T cells and enhance their antitumor responses are also summarized.

SCIENCE IMMUNOLOGY (2023)

Add to Collection
Review Immunology

Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines

K. Swetha et al.

Summary: Lipid nanoparticles (LNPs) are an advanced technology for efficient in vivo delivery of exogenous mRNA, especially for COVID-19 vaccines. LNPs consist of four different lipids: ionizable lipids, helper or neutral lipids, cholesterol, and lipids attached to polyethylene glycol (PEG). This review presents recent advances and insights in LNPs design, composition, and properties, with a focus on COVID-19 vaccine development. The role of ionizable lipids in mRNA vaccines and the use of LNPs as effective delivery vehicles for vaccination, genome editing, and protein replacement therapy are discussed.

VACCINES (2023)

Add to Collection
Article Chemistry, Multidisciplinary

Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy

Zhenmei Yang et al.

Summary: Hepatocellular carcinoma (HCC) is a prevalent and lethal disease, and effective therapies for advanced HCC are limited. To address this, researchers developed a strategy that transforms macrophages into chimeric antigen receptor macrophages (CAR-Ms) to enhance HCC cell-directed phagocytosis and tumoricidal immunity. Using lipid nanoparticles (LNPs) that target liver macrophages, mRNA encoding CAR and Siglec-G lacking ITIMs (Siglec-G & UDelta;ITIMs) were delivered to liver macrophages, resulting in improved phagocytic function, reduced tumor burden, and increased survival in an HCC mouse model. These findings suggest a promising approach for HCC treatment that should be further evaluated in clinical trials.

JOURNAL OF CONTROLLED RELEASE (2023)

Add to Collection
Article Medicine, Research & Experimental

The application of HER2 and CD47 CAR-macrophage in ovarian cancer

Yizhao Chen et al.

Summary: This study constructed CAR-Ms targeting HER2 and CD47, demonstrating their ability to phagocytose ovarian cancer cells and activate CD8+ cytotoxic T lymphocytes. In vivo models showed that CAR-Ms enhanced CD8+ T cell activation and led to tumor regression by affecting the tumor microenvironment.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Add to Collection
Article Oncology

Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer

Xuhui Dong et al.

Summary: Researchers have developed a novel macrophage-based therapy for gastric cancer and investigated its anti-tumoral effects. The therapy specifically targeted HER2-expressed gastric cancer in vitro and in vivo. The combination of this therapy with oxaliplatin showed enhanced efficacy.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection
Review Cell Biology

Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity

Senbo Liu et al.

Summary: This review summarizes the effects of radiotherapy on the cellular components of the tumor microenvironment, including T cells, macrophages, and other myeloid cells, as well as non-cellular components like lactate and extracellular vesicles. It also discusses the impact of different radiotherapy modalities on tumor immunity and issues related to the clinical practice of combination therapy.

CELL DEATH & DISEASE (2023)

Add to Collection
Article Multidisciplinary Sciences

Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors

Xudong Wang et al.

Summary: This study identifies ACOD1 as a key regulator of the pro-inflammatory state in macrophages. Depletion of ACOD1 in CAR-macrophages enhances their polarization towards a pro-inflammatory state, leading to increased reactive oxygen species production, phagocytosis, and cytotoxic functions against cancer cells. ACOD1-depleted CAR-macrophages also exhibit enhanced tumor repression capacity in ovarian or pancreatic cancer mouse models, especially when combined with immune checkpoint inhibitors.

NATURE COMMUNICATIONS (2023)

Add to Collection
Article Chemistry, Multidisciplinary

Photoresponsive Vaccine-Like CAR-M System with High-Efficiency Central Immune Regulation for Inflammation-Related Depression

Yu Liu et al.

Summary: Microglia-induced neuroinflammation is crucial in the development of depression. Researchers have developed a light-responsive system called UZPM, which can be introduced into macrophages and targeted to centrally activated microglia. Experimental results show that the CAR-M-UZPM drug delivery system can efficiently penetrate the blood-brain barrier, inhibit the M1 polarization of microglia, and prevent the occurrence and development of inflammation-related depression.

ADVANCED MATERIALS (2022)

Add to Collection
Article Gastroenterology & Hepatology

CXCR2 inhibition enables NASH-HCC immunotherapy

Jack Leslie et al.

Summary: This study found that targeting neutrophils using a CXCR2 small molecule inhibitor can enhance the sensitivity of non-alcoholic steatohepatitis-associated hepatocellular carcinoma (NASH-HCC) to immune checkpoint inhibition therapy (ICI). The combination therapy can reprogram the tumor immune microenvironment, increase the number of anti-tumor immune cells, and improve treatment outcomes.

GUT (2022)

Add to Collection
Review Biochemistry & Molecular Biology

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Alexander Dimitri et al.

Summary: Chimeric Antigen Receptor (CAR) T-cells have revolutionized personalized cancer therapy, but their effectiveness in many other cancers, especially solid tumors, has not reached its full potential. The use of CRISPR-Cas9 gene editing technology can address the limitations of CAR T-cell therapy and open new avenues for research to optimize its efficacy.

MOLECULAR CANCER (2022)

Add to Collection
Article Cell Biology

Ex Vivo Generation of CAR Macrophages from Hematopoietic Stem and Progenitor Cells for Use in Cancer Therapy

Daniela Paasch et al.

Summary: CAR T-cell therapies have shown impressive results in hematological malignancies but little success in solid tumors. Recent studies have identified macrophages as a potential candidate for CAR approach and using primary human HSPCs as a cell source to generate CAR M phi s has shown promising results in solid tumor therapy.

CELLS (2022)

Add to Collection
Article Cell Biology

CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro

Maoxuan Liu et al.

Summary: CAR-M has the potential to improve cancer therapy, and different intracellular signaling domains have different effects on CAR-M functions. CAR-M and CAR-T cells can synergize to kill tumor cells by regulating the expression of costimulatory ligands and polarization of macrophages to enhance cytotoxicity.

CELLS (2022)

Add to Collection
Review Immunology

The complex role of tumor-infiltrating macrophages

Anthos Christofides et al.

Summary: This article reviews the characteristics of tumor-associated macrophages (TAMs) and discusses the mechanisms that contribute to their pathological adaptations to the tumor microenvironment. TAMs play a crucial role in the tumor microenvironment and are closely associated with cancer progression.

NATURE IMMUNOLOGY (2022)

Add to Collection
Review Biotechnology & Applied Microbiology

Macrophages as tools and targets in cancer therapy

Alberto Mantovani et al.

Summary: This review discusses the molecular mechanisms of macrophage reprogramming in the tumor microenvironment and provides an overview of macrophage-targeted therapies for cancer treatment.

NATURE REVIEWS DRUG DISCOVERY (2022)

Add to Collection
Article Cell Biology

Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy

Chen Chen et al.

Summary: Researchers have developed a cavity-injectable nanoporter-hydrogel superstructure to prevent relapse of glioblastoma multiforme (GBM). This superstructure introduces glioma stem cell-specific chimeric antigen receptor (CAR) genes into macrophages/microglia, stimulating an antitumor immune response and preventing postoperative relapse.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection
Article Cell Biology

Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy

Yun Chang et al.

Summary: This study genetically engineered human pluripotent stem cells with synthetic CARs, resulting in the differentiation into functional CAR neutrophils. These CAR neutrophils demonstrated superior cytotoxicity against tumor cells, providing a potential strategy for cancer treatment.

CELL REPORTS (2022)

Add to Collection
Article Oncology

Hypoxia-inducible lentiviral gene expression in engineered human macrophages

Harrison K. Chinn et al.

Summary: This study demonstrates the engineering of human macrophages to conditionally express genes under hypoxic conditions, allowing for localized gene delivery in cancer. The engineered macrophages were able to express therapeutic proteins in a controlled manner, making them ideal vehicles for delivering payloads in hypoxic tissues.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection
Article Immunology

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages

Tobias Zeller et al.

Summary: Blocking both CD47 and LILRB1 can enhance the phagocytosis of lymphoma cells by macrophages, improving the efficacy of antibody therapy for chronic lymphocytic leukemia and lymphomas.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection
Article Immunology

Targeted nanoparticles modify neutrophil function in vivo

Sandra Vols et al.

Summary: This article describes the discovery of peptides that specifically bind to neutrophils and the development of nanoparticles decorated with these peptides for neutrophil-specific targeting. The study also demonstrates the specific modulation of neutrophil function and longevity by encapsulating neutrophil modifying small molecules within these nanoparticles.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection
Article Biochemistry & Molecular Biology

Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

Andreas Mackensen et al.

Summary: A study of five patients with refractory systemic lupus erythematosus treated with anti-CD19 CAR T cell therapy showed remission of SLE disease in all patients after 3 months, and long-term drug-free remission was maintained during follow-up.

NATURE MEDICINE (2022)

Add to Collection
Meeting Abstract Oncology

A PHASE 1, FIRST IN HUMAN (FIH) STUDY OF AUTOLOGOUS MACROPHAGES CONTAINING AN ANTIHER2 CHIMERIC ANTIGEN RECEPTOR (CAR) IN PARTICIPANTS WITH HER2 OVEREXPRESSING SOLID TUMORS

Kim Reiss et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection
Review Oncology

Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

M-L Schubert et al.

Summary: CAR T-cell therapy targeting CD19-expressing B cells has shown promising results in treating refractory and/or relapsed B-cell malignancies, but also presents challenges such as cytokine release syndrome and neurotoxicity syndrome. Optimal management strategies for the side-effects associated with CAR T-cell therapy are crucial as it expands into other diseases in hematology and oncology.

ANNALS OF ONCOLOGY (2021)

Add to Collection
Review Oncology

Macrophage-Based Approaches for Cancer Immunotherapy

Nicholas R. Anderson et al.

Summary: Adoptive cell therapy with genetically modified T cells has shown promising results in hematologic malignancies, but applying it to solid tumors has been challenging. This has led to the investigation of alternative immune cells as therapeutic options. Macrophages have functional plasticity that can be harnessed for both antitumor and protumor effects, leading to efforts to deplete or repolarize tumor-associated macrophages, as well as exploring the potential of adoptively transferring genetically modified macrophages.

CANCER RESEARCH (2021)

Add to Collection
Article Oncology

Chimeric antigen receptor-modified macrophages trigger systemic anti-tumour immunity

Zhiyuan Niu et al.

Summary: Research has identified immunosuppressive cells with high lipid droplets accumulation in tumor tissues. By using engineered CAR-Ms, these cells can be targeted to inhibit their migration and induce systemic anti-tumor immunity, thereby prolonging survival.

JOURNAL OF PATHOLOGY (2021)

Add to Collection
Review Immunology

Monocytes, macrophages, dendritic cells and neutrophils: an update on lifespan kinetics in health and disease

Amit A. Patel et al.

Summary: Phagocytes are a crucial part of the immune cell family, playing a role in tissue maintenance and immune response orchestration. Understanding the kinetic profiles of these cells during inflammation can help in developing rational therapies to boost or reduce their production as needed.

IMMUNOLOGY (2021)

Add to Collection
Review Immunology

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors

Christopher Sloas et al.

Summary: Cellular immunotherapies, particularly using macrophages as adoptive cell therapies, show promise in treating solid tumors. Engineered CAR macrophages (CAR-M) have the potential for effective treatment against solid malignancies, highlighting the importance of manipulating immune cell function in cancer therapy.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection
Review Nanoscience & Nanotechnology

Recent Advances in Macrophage-Mediated Drug Delivery Systems

Tiantian Liang et al.

Summary: Macrophages play a crucial role in drug delivery systems, prolonging drug circulation and release, enhancing stability and targeting ability. However, further research and optimization are needed for their potential applications.

INTERNATIONAL JOURNAL OF NANOMEDICINE (2021)

Add to Collection
Review Cell Biology

Macrophage Reprogramming and Cancer Therapeutics: Role of iNOS-Derived NO

Khosrow Kashfi et al.

Summary: Nitric oxide production by iNOS plays a critical role in tumor promotion or suppression through influencing macrophage polarization. Manipulating macrophage plasticity to enhance tumoricidal defenses is a potential therapeutic strategy in cancer treatment. Regulatory pathways and immunomodulation targeting macrophage polarization may inhibit the immunosuppressive tumor microenvironment.

CELLS (2021)

Add to Collection
Review Oncology

CAR-T cell therapy: current limitations and potential strategies

Robert C. Sterner et al.

Summary: CAR-T cell therapy has shown remarkable clinical responses in certain subsets of leukemia or lymphoma, but faces challenges in solid tumors and hematological malignancies. Innovative strategies and approaches are necessary to overcome these challenges and improve the efficacy of CAR-T cells.

BLOOD CANCER JOURNAL (2021)

Add to Collection
Article Chemistry, Multidisciplinary

Nanocomplex-Mediated In Vivo Programming to Chimeric Antigen Receptor-M1 Macrophages for Cancer Therapy

Mikyung Kang et al.

Summary: The study proposes a simple method to transform macrophages that can naturally infiltrate solid tumors into CAR-M1 macrophages with enhanced cancer-directed phagocytosis and anti-tumor activity. Injected nanocomplexes of macrophage-targeting nanocarriers and CAR-interferon-gamma-encoding plasmid DNA induce CAR-M1 macrophages capable of CAR-mediated cancer phagocytosis, tumor immunomodulation, and inhibiting solid tumor growth, providing an effective off-the-shelf CAR-macrophage therapy for solid tumors without the need for complex and costly ex vivo CAR-cell manufacturing processes.

ADVANCED MATERIALS (2021)

Add to Collection
Article Multidisciplinary Sciences

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance

Rosalynd Upton et al.

Summary: Trastuzumab, a targeted anti-HER2 monoclonal antibody, is effective for early-stage HER2(+) breast cancer but resistance often develops in advanced-stage patients. Combining trastuzumab with anti-CD47 immunotherapy shows promising results in inhibiting the growth of ADCC-tolerant HER2(+) breast cancers.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection
Article Immunology

CAR Macrophages for SARS-CoV-2 Immunotherapy

Wenyan Fu et al.

Summary: The study found that CAR(MERTK) macrophages can mediate similar SARS-CoV-2 clearance in vitro and reduce the viral load without upregulation of proinflammatory cytokine expression. These results pave the way for further investigation of CARs for the treatment of COVID-19 patients, especially those with severe cases.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection
Review Cell Biology

Macrophages Derived From Human Induced Pluripotent Stem Cells: The Diversity of Protocols, Future Prospects, and Outstanding Questions

Irina Lyadova et al.

Summary: iMphs derived from induced pluripotent stem cells offer a novel and promising model for studying human M phi function and differentiation, and for developing new therapeutic strategies. However, the current variability in iMph differentiation protocols highlights the need for standardization and identification of minimum required conditions to enable large-scale, cost-effective, and clinically suitable generation of iMphs.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection
Review Biotechnology & Applied Microbiology

Neutrophils as emerging therapeutic targets

Tamas Nemeth et al.

NATURE REVIEWS DRUG DISCOVERY (2020)

Add to Collection
Article Cell Biology

Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma

Dongrui Wang et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

Add to Collection
Review Pharmacology & Pharmacy

The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy

Qiyao Yang et al.

ACTA PHARMACEUTICA SINICA B (2020)

Add to Collection
Article Biotechnology & Applied Microbiology

Human chimeric antigen receptor macrophages for cancer immunotherapy

Michael Klichinsky et al.

NATURE BIOTECHNOLOGY (2020)

Add to Collection
Article Chemistry, Medicinal

Myeloid Differentiation Primary Response Protein 88 (MyD88): The Central Hub of TLR/IL-1R Signaling

Lingfeng Chen et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Add to Collection
Review Oncology

Systemic Reprogramming of Monocytes in Cancer

Mate Kiss et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection
Meeting Abstract Oncology

CAR MACROPHAGES (CAR-M) ELICIT A SYSTEMIC ANTITUMOR IMMUNE RESPONSE AND SYNERGIZE WITH PD1 BLOCKADE IN IMMUNOCOMPETENT MOUSE MODELS OF HER2+SOLID TUMORS

Stefano Pierini et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection
Article Oncology

Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma

Jennifer L. Gardell et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection
Article Oncology

Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses

Katherine J. Brempelis et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection
Letter Oncology

Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions

Li Zhang et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection
Article Biochemistry & Molecular Biology

Antibody-secreting macrophages generated using CpG-free plasmid eliminate tumor cells through antibody-dependent cellular phagocytosis

Eun Bi Cha et al.

BMB REPORTS (2020)

Add to Collection
Review Oncology

Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment

Yuting Zhang et al.

CANCER BIOLOGY & MEDICINE (2020)

Add to Collection
Review Hematology

Neutrophil plasticity in the tumor microenvironment

Morgan A. Giese et al.

BLOOD (2019)

Add to Collection
Article Cell & Tissue Engineering

Cell Subtypes Within the Liver Microenvironment Differentially Interact with Lipid Nanoparticles

Cory D. Sago et al.

CELLULAR AND MOLECULAR BIOENGINEERING (2019)

Add to Collection
Article Multidisciplinary Sciences

CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy

Amira A. Barkal et al.

NATURE (2019)

Add to Collection
Review Immunology

The Remarkable Plasticity of Macrophages: A Chance to Fight Cancer

Nadege Bercovici et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection
Article Pathology

Diversity, Mechanisms, and Significance of Macrophage Plasticity

Massimo Locati et al.

Annual Review of Pathology-Mechanisms of Disease (2019)

Add to Collection
Article Oncology

Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix

Wenlong Zhang et al.

BRITISH JOURNAL OF CANCER (2019)

Add to Collection
Article Biochemistry & Molecular Biology

Safety profile of autologous macrophage therapy for liver cirrhosis

Francesca Moroni et al.

NATURE MEDICINE (2019)

Add to Collection
Review Hematology

CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products

Julio C. Chavez et al.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)

Add to Collection
Article Gastroenterology & Hepatology

Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

Timothy M. Nywening et al.

GUT (2018)

Add to Collection
Review Cell Biology

CAR-T cells: the long and winding road to solid tumors

Maria Michela D'Aloia et al.

CELL DEATH & DISEASE (2018)

Add to Collection
Article Biology

Chimeric antigen receptors that trigger phagocytosis

Meghan A. Morrissey et al.

ELIFE (2018)

Add to Collection
Review Physiology

Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types?

Carlos Rosales

FRONTIERS IN PHYSIOLOGY (2018)

Add to Collection
Article Biotechnology & Applied Microbiology

Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape

Carl DeSelm et al.

MOLECULAR THERAPY (2018)

Add to Collection
Review Biotechnology & Applied Microbiology

Targeting macrophages: therapeutic approaches in cancer

Luca Cassetta et al.

NATURE REVIEWS DRUG DISCOVERY (2018)

Add to Collection
Article Pharmacology & Pharmacy

Primary M1 macrophages as multifunctional carrier combined with PLGA nanoparticle delivering anticancer drug for efficient glioma therapy

Liang Pang et al.

DRUG DELIVERY (2018)

Add to Collection
Article Oncology

NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma

Tobias Weiss et al.

CANCER RESEARCH (2018)

Add to Collection
Article Immunology

The fate and lifespan of human monocyte subsets in steady state and systemic inflammation

Amit A. Patel et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2017)

Add to Collection
Article Biochemistry & Molecular Biology

THP-1 and human peripheral blood mononuclear cell-derived macrophages differ in their capacity to polarize in vitro

Hiromi Shiratori et al.

MOLECULAR IMMUNOLOGY (2017)

Add to Collection
Article Biochemistry & Molecular Biology

Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance

Donnele Daley et al.

NATURE MEDICINE (2017)

Add to Collection
Article Nanoscience & Nanotechnology

Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence

Jingwei Xue et al.

NATURE NANOTECHNOLOGY (2017)

Add to Collection
Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection
Article Oncology

HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial

Nabil Ahmed et al.

JAMA ONCOLOGY (2017)

Add to Collection
Review Oncology

A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy

Ming Yang et al.

CANCER BIOLOGY & THERAPY (2017)

Add to Collection
Review Cell & Tissue Engineering

Granulocyte transfusions: A concise review for practitioners

Juan Gea-Banacloche

CYTOTHERAPY (2017)

Add to Collection
Article Hematology

Human neutrophil kinetics: modeling of stable isotope labeling data supports short blood neutrophil half-lives

Julio Lahoz-Beneytez et al.

BLOOD (2016)

Add to Collection
Article Chemistry, Multidisciplinary

Macrophage-based cell therapies: The long and winding road

Simon Lee et al.

JOURNAL OF CONTROLLED RELEASE (2016)

Add to Collection
Review Cell Biology

Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment

Jaehong Kim et al.

MEDIATORS OF INFLAMMATION (2016)

Add to Collection
Review Oncology

Chimeric antigen receptor T-cell therapy for solid tumors

Kheng Newick et al.

MOLECULAR THERAPY-ONCOLYTICS (2016)

Add to Collection
Article Oncology

Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo

Ali Roghanian et al.

CANCER CELL (2015)

Add to Collection
Article Chemistry, Multidisciplinary

Macrophage mediated biomimetic delivery system for the treatment of lung metastasis of breast cancer

Jijun Fu et al.

JOURNAL OF CONTROLLED RELEASE (2015)

Add to Collection
Article Chemistry, Multidisciplinary

Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury

Simonetta Papa et al.

JOURNAL OF CONTROLLED RELEASE (2014)

Add to Collection
Review Immunology

From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation

Paola Italiani et al.

FRONTIERS IN IMMUNOLOGY (2014)

Add to Collection
Article Oncology

Human polymorphonuclear neutrophils specifically recognize and kill cancerous cells

Jun Yan et al.

ONCOIMMUNOLOGY (2014)

Add to Collection
Article Multidisciplinary Sciences

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

Diane Tseng et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

Add to Collection
Review Immunology

How Samhd1 changes our view of viral restriction

Nadine Laguette et al.

TRENDS IN IMMUNOLOGY (2012)

Add to Collection
Article Biochemistry & Molecular Biology

Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy

S. Senju et al.

GENE THERAPY (2011)

Add to Collection
Article Multidisciplinary Sciences

Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein

Kasia Hrecka et al.

NATURE (2011)

Add to Collection
Review Immunology

Biocompatibility of implants: lymphocyte/macrophage interactions

James M. Anderson et al.

SEMINARS IN IMMUNOPATHOLOGY (2011)

Add to Collection
Article Gastroenterology & Hepatology

Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy

Gerben J. van der Bij et al.

JOURNAL OF HEPATOLOGY (2010)

Add to Collection
Review Rheumatology

Neutrophil function in inflammation and inflammatory diseases

Helen L. Wright et al.

RHEUMATOLOGY (2010)

Add to Collection
Article Oncology

Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: N1 versus N2 TAN

Zvi G. Fridlender et al.

CANCER CELL (2009)

Add to Collection
Article Oncology

Tumor-targeted interferon-α delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis

Michele De Palma et al.

CANCER CELL (2008)

Add to Collection
Review Oncology

Macrophage activation by endogenous danger signals

X. Zhang et al.

JOURNAL OF PATHOLOGY (2008)

Add to Collection
Article Biochemistry & Molecular Biology

Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo

A Biglari et al.

GENE THERAPY (2006)

Add to Collection
Article Virology

Transduction of nondividing human macrophages with gammaretrovirus-derived vectors

L Jarrosson-Wuilleme et al.

JOURNAL OF VIROLOGY (2006)

Add to Collection
Article Biotechnology & Applied Microbiology

Spleen necrosis virus-derived C-type retroviral vectors for gene transfer to quiescent cells

Z Parveen et al.

NATURE BIOTECHNOLOGY (2000)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.